Closure Medical
This article was originally published in The Gray Sheet
Executive Summary
Raleigh N.C. firm has yet to sign a marketing partner for its vascular sealant device, which will be promoted as a stronger, easier-to-use alternative to Baxter's Tisseel and Cryolife's BioGlue after receiving PMA approval. Johnson & Johnson, Closure's marketing partner for its Band-Aid liquid bandage, is not aiding the firm in developing a marketing strategy for the vascular sealant, as reported in "The Gray Sheet" (1"The Gray Sheet" Feb. 23, 2004, p. 17)...
You may also be interested in...
Closure Medical Vascular Sealant Will Challenge Baxter, CryoLife Products
Closure Medical plans to focus 2004 R&D efforts on preparing and completing a definitive clinical trial for a vascular sealant device that the firm will promote as a stronger, easier-to-use alternative to Baxter's Tisseel and CryoLife's BioGlue
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.